Molecular mechanisms of glucocorticoids action: From basic research to clinical implications

Current Immunology Reviews

Volumn 6, Issue 4, 2010, Pages 371-380

  Liberman, Ana C ^a   Castro, Carla N ^a   Noguerol, Maria Antunica ^a   Tabarrozzi, Andres E Barcala ^a   Druker, Jimena ^a   Perone, Marcelo J ^a   Arzt, Eduardo ^a  

^a INSTITUTO DE FISIOLOGÍA   (Argentina)

Author keywords

Glucocorticoids; Inflammation; Molecular interaction; Transcription factors

Indexed keywords

AZIRIDINE DERIVATIVE; BRG1 PROTEIN; COACTIVATOR ASSOCIATED ARGININE METHYLTRANSFERASE 1; COMPOUND A; CORTICOSTEROID DERIVATIVE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; DEOXYRIBONUCLEASE I; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HISTONE ACETYLTRANSFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHYLTRANSFERASE; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEAR RECEPTOR COACTIVATOR 2; PHENYLETHANOLAMINE N METHYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PROTEIN KINASE B; PROTEIN P300; RU 24858; STEROID RECEPTOR COACTIVATOR 1; TRANSCRIPTION FACTOR AP 1; TYROSINE AMINOTRANSFERASE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELLULAR IMMUNITY; CHRONIC INFLAMMATION; CONFORMATIONAL TRANSITION; DNA BINDING; DRUG MECHANISM; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE REPRESSION; GENETIC TRANSCRIPTION; HORMONE RESPONSIVE ELEMENT; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE SYSTEM; INFLAMMATORY DISEASE; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; PROTEIN PROTEIN INTERACTION; TRANSACTIVATION; TRANSCRIPTION REGULATION;

EID: 78649254005     PISSN: 15733955     EISSN: None     Source Type: Journal    
DOI: 10.2174/1573395511006040371     Document Type: Article

References (134)

1. Besedovsky HO, del Rey A. Immune-neuroendocrine circuits: integrative role of cytokines. Front Neuroendocrinol 1992; 13: 61-94.
2. Refojo D, Liberman AC, Giacomini D, et al. Integrating systemic information at the molecular level: cross-talk between steroid receptors and cytokine signaling on different target cells. Ann N Y Acad Sci 2003; 992: 196-204.
3. Refojo D, Liberman AC, Holsboer F, Arzt E. Transcription factormediated molecular mechanisms involved in the functional crosstalk between cytokines and glucocorticoids. Immunol Cell Biol 2001; 79: 385-94.
4. Liberman AC, Refojo D, Arzt E. Cytokine signaling/transcription factor cross-talk in T cell activation and Th1-Th2 differentiation. Arch Immunol Ther Exp (Warsz) 2003; 51: 351-65.
5. Liberman AC, Druker J, Garcia FA, Holsboer F, Arzt E. Intracellular molecular signaling. Basis for specificity to glucocorticoid anti-inflammatory actions. Ann N Y Acad Sci 2009; 1153: 6-13.
6. Liberman AC, Druker J, Perone MJ, Arzt E. Glucocorticoids in the regulation of transcription factors that control cytokine synthesis. Cytokine Growth Factor Rev 2007; 18: 45-56.
7. Druker J, Liberman AC, Acuna M, et al. Molecular understanding of cytokine-steroid hormone dialogue: implications for human diseases. Ann N Y Acad Sci 2006; 1088: 297-306.
8. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 2005; 353: 1711-23.
9. Stahn C, Lowenberg M, Hommes DW, Buttgereit F. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol 2007; 275: 71-8.
10. Schmidt BM, Gerdes D, Feuring M, Falkenstein E, Christ M, Wehling M. Rapid, nongenomic steroid actions: A new age? Front Neuroendocrinol 2000; 21: 57-94.
11. Croxtall JD, Choudhury Q, Flower RJ. Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcriptionindependent mechanism. Br J Pharmacol 2000; 130: 289-98.
12. Buttgereit F, Scheffold A. Rapid glucocorticoid effects on immune cells. Steroids 2002; 67: 529-34.
13. Limbourg FP, Huang Z, Plumier JC, et al. Rapid nontranscriptional activation of endothelial nitric oxide synthase mediates increased cerebral blood flow and stroke protection by corticosteroids. J Clin Invest 2002; 110: 1729-38.
14. Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 2004; 50: 3408-17.
15. Song IH, Gold R, Straub RH, Burmester GR, Buttgereit F. New Glucocorticoids on the Horizon: Repress, Don't Activate! J Rheumatol 2005; 32: 1199-1207.
16. Lowenberg M, Tuynman J, Bilderbeek J, et al. Rapid immunosuppressive effects of glucocorticoids mediated through Lck and Fyn. Blood 2005; 106: 1703-10.
17. Lowenberg M, Verhaar AP, Bilderbeek J, et al. Glucocorticoids cause rapid dissociation of a T-cell-receptor-associated protein complex containing LCK and FYN. EMBO Rep 2006; 7: 1023-9.
18. Schacke H, Schottelius A, Docke WD, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA 2004; 101: 227-32.
19. Thompson EB. Steroids, gene expression, and apoptosis: recollections of contributions and controversies. Steroids 1998; 63: 368-74.
20. Ismaili N, Garabedian MJ. Modulation of glucocorticoid receptor function via phosphorylation. Ann N Y Acad Sci 2004; 1024: 86-101.
21. Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood) 2003; 228: 111-33.
22. Savory JG, Hsu B, Laquian IR, et al. Discrimination between NL1-and NL2-mediated nuclear localization of the glucocorticoid receptor. Mol Cell Biol 1999; 19: 1025-37.
23. De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev 2003; 24: 488-522.
24. Ashwell JD, Lu FW, Vacchio MS. Glucocorticoids in T cell development and function*. Annu Rev Immunol 2000; 18: 309-45.
25. Becker PB, Gloss B, Schmid W, Strahle U, Schutz G. In vivo protein-DNA interactions in a glucocorticoid response element require the presence of the hormone. Nature 1986; 324: 686-8.
26. Carrigan A, Walther RF, Salem HA, et al. An active nuclear retention signal in the glucocorticoid receptor functions as a strong inducer of transcriptional activation. J Biol Chem 2007; 282: 10963-71.
27. Meijsing SH, Elbi C, Luecke HF, Hager GL, Yamamoto KR. The ligand binding domain controls glucocorticoid receptor dynamics independent of ligand release. Mol Cell Biol 2007; 27: 2442-51.
28. Felts SJ, Toft DO. p23, a simple protein with complex activities. Cell Stress Chaperones 2003; 8: 108-13.
29. Fletcher TM, Xiao N, Mautino G, et al. ATP-dependent mobilization of the glucocorticoid receptor during chromatin remodeling. Mol Cell Biol 2002; 22: 3255-63.
30. Freeman BC, Felts SJ, Toft DO, Yamamoto KR. The p23 molecular chaperones act at a late step in intracellular receptor action to differentially affect ligand efficacies. Genes Dev 2000; 14: 422-34.
31. John S, Sabo PJ, Johnson TA, et al. Interaction of the glucocorticoid receptor with the chromatin landscape. Mol Cell 2008; 29: 611-24.
32. Yoshinaga SK, Peterson CL, Herskowitz I, Yamamoto KR. Roles of SWI1, SWI2, and SWI3 proteins for transcriptional enhancement by steroid receptors. Science 1992; 258: 1598-604.
33. Cairns BR, Levinson RS, Yamamoto KR, Kornberg RD. Essential role of Swp73p in the function of yeast Swi/Snf complex. Genes Dev 1996; 10: 2131-44.
34. He Y, Simons SS, Jr. STAMP, a novel predicted factor assisting TIF2 actions in glucocorticoid receptor-mediated induction and repression. Mol Cell Biol 2007; 27: 1467-85.
35. Strahl BD, Briggs SD, Brame CJ, et al. Methylation of histone H4 at arginine 3 occurs in vivo and is mediated by the nuclear receptor coactivator PRMT1. Curr Biol 2001; 11: 996-1000.
36. Chen D, Ma H, Hong H, et al. Regulation of transcription by a protein methyltransferase. Science 1999; 284: 2174-7.
37. Banach T, Zurowski D, Gil K, Weisbrodt NW, Rosenfeld G, Thor PJ. Peripheral mechanisms of intestinal dysmotility in the morphine tolerant and dependent rats. J Physiol Pharmacol 2006; 57: 73-82.
38. Kleiman A, Tuckermann JP. Glucocorticoid receptor action in beneficial and side effects of steroid therapy: lessons from conditional knockout mice. Mol Cell Endocrinol 2007; 275: 98-108.
39. Newton R, Holden NS. Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor? Mol Pharmacol 2007; 72: 799-809.
40. Tobler A, Meier R, Seitz M, Dewald B, Baggiolini M, Fey MF. Glucocorticoids downregulate gene expression of GM-CSF, NAP-1/IL-8, and IL-6, but not of M-CSF in human fibroblasts. Blood 1992; 79: 45-51.
41. Newton R, Hart LA, Stevens DA, et al. Effect of dexamethasone on interleukin-1beta-(IL-1beta)-induced nuclear factor-kappaB (NF-kappaB) and kappaB-dependent transcription in epithelial cells. Eur J Biochem 1998; 254: 81-9.
42. Chivers JE, Gong W, King EM, et al. Analysis of the dissociated steroid RU24858 does not exclude a role for inducible genes in the anti-inflammatory actions of glucocorticoids. Mol Pharmacol 2006; 70: 2084-95.
43. Poon M, Liu B, Taubman MB. Identification of a novel dexamethasone-sensitive RNA-destabilizing region on rat monocyte chemoattractant protein 1 mRNA. Mol Cell Biol 1999; 19: 6471-8.
44. Lasa M, Brook M, Saklatvala J, Clark AR. Dexamethasone destabilizes cyclooxygenase 2 mRNA by inhibiting mitogenactivated protein kinase p38. Mol Cell Biol 2001; 21: 771-80.
45. Lai WS, Carballo E, Strum JR, Kennington EA, Phillips RS, Blackshear PJ. Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor alpha mRNA. Mol Cell Biol 1999; 19: 4311-23.
46. Dean JL, Sully G, Clark AR, Saklatvala J. The involvement of AUrich element-binding proteins in p38 mitogen-activated protein kinase pathway-mediated mRNA stabilisation. Cell Signal 2004; 16: 1113-21.
47. Zhao Q, Shepherd EG, Manson ME, Nelin LD, Sorokin A, Liu Y. The role of mitogen-activated protein kinase phosphatase-1 in the response of alveolar macrophages to lipopolysaccharide: attenuation of proinflammatory cytokine biosynthesis via feedback control of p38. J Biol Chem 2005; 280: 8101-8.
48. Lasa M, Abraham SM, Boucheron C, Saklatvala J, Clark AR. Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol Cell Biol 2002; 22: 7802-11.
49. Newton R, Holden N. Inhibitors of p38 mitogen-activated protein kinase: potential as anti-inflammatory agents in asthma? Bio Drugs 2003; 17: 113-29.
50. Wesselborg S, Bauer MK, Vogt M, Schmitz ML, Schulze-Osthoff K. Activation of transcription factor NF-kappaB and p38 mitogenactivated protein kinase is mediated by distinct and separate stress effector pathways. J Biol Chem 1997; 272: 12422-9.
51. Ayroldi E, Riccardi C. Glucocorticoid-induced leucine zipper (GILZ): a new important mediator of glucocorticoid action. FASEB J 2009.
52. Godot V, Garcia G, Capel F, et al. Dexamethasone and IL-10 stimulate glucocorticoid-induced leucine zipper synthesis by human mast cells. Allergy 2006; 61: 886-90.
53. Eddleston J, Herschbach J, Wagelie-Steffen AL, Christiansen SC, Zuraw BL. The anti-inflammatory effect of glucocorticoids is mediated by glucocorticoid-induced leucine zipper in epithelial cells. J Allergy Clin Immunol 2007; 119: 115-22.
54. Ayroldi E, Zollo O, Macchiarulo A, Di Marco B, Marchetti C, Riccardi C. Glucocorticoid-induced leucine zipper inhibits the Rafextracellular signal-regulated kinase pathway by binding to Raf-1. Mol Cell Biol 2002; 22: 7929-41.
55. Webster JC, Jewell CM, Bodwell JE, Munck A, Sar M, Cidlowski JA. Mouse glucocorticoid receptor phosphorylation status influences multiple functions of the receptor protein. J Biol Chem 1997; 272: 9287-93.
56. Hittelman AB, Burakov D, Iniguez-Lluhi JA, Freedman LP, Garabedian MJ. Differential regulation of glucocorticoid receptor transcriptional activation via AF-1-associated proteins. EMBO J 1999; 18: 5380-8.
57. Itoh M, Adachi M, Yasui H, Takekawa M, Tanaka H, Imai K. Nuclear export of glucocorticoid receptor is enhanced by c-Jun Nterminal kinase-mediated phosphorylation. Mol Endocrinol 2002; 16: 2382-92.
58. Krstic MD, Rogatsky I, Yamamoto KR, Garabedian MJ. Mitogenactivated and cyclin-dependent protein kinases selectively and differentially modulate transcriptional enhancement by the glucocorticoid receptor. Mol Cell Biol 1997; 17: 3947-54.
59. Rogatsky I, Logan SK, Garabedian MJ. Antagonism of glucocorticoid receptor transcriptional activation by the c-Jun Nterminal kinase. Proc Natl Acad Sci USA 1998; 95: 2050-5.
60. Szatmary Z, Garabedian MJ, Vilcek J. Inhibition of glucocorticoid receptor-mediated transcriptional activation by p38 mitogenactivated protein (MAP) kinase. J Biol Chem 2004; 279: 43708-15.
61. Irusen E, Matthews JG, Takahashi A, Barnes PJ, Chung KF, Adcock IM. p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 2002; 109: 649-57.
62. Chen MS, Silverstein AM, Pratt WB, Chinkers M. The tetratricopeptide repeat domain of protein phosphatase 5 mediates binding to glucocorticoid receptor heterocomplexes and acts as a dominant negative mutant. J Biol Chem 1996; 271: 32315-20.
63. Somers JP, DeFranco DB. Effects of okadaic acid, a protein phosphatase inhibitor, on glucocorticoid receptor-mediated enhancement. Mol Endocrinol 1992; 6: 26-34.
64. DeFranco DB, Qi M, Borror KC, Garabedian MJ, Brautigan DL. Protein phosphatase types 1 and/or 2A regulate nucleocytoplasmic shuttling of glucocorticoid receptors. Mol Endocrinol 1991; 5: 1215-28.
65. De Bosscher K, Haegeman G. Minireview: latest perspectives on antiinflammatory actions of glucocorticoids. Mol Endocrinol 2009; 23: 281-91.
66. Beato M, Herrlich P, Schutz G. Steroid hormone receptors: many actors in search of a plot. Cell 1995; 83: 851-7.
67. Stocklin E, Wissler M, Gouilleux F, Groner B. Functional interactions between Stat5 and the glucocorticoid receptor. Nature 1996; 383: 726-8.
68. Liberman AC, Refojo D, Druker J, et al. The activated glucocorticoid receptor inhibits the transcription factor T-bet by direct protein-protein interaction. FASEB J 2007; 21: 1177-88.
69. Ohtsuka T, Kubota A, Hirano T, et al. Glucocorticoid-mediated gene suppression of rat cytokine-induced neutrophil chemoattractant CINC/gro, a member of the interleukin-8 family, through impairment of NF-kappa B activation. J Biol Chem 1996; 271: 1651-9.
70. Mukaida N, Morita M, Ishikawa Y, et al. Novel mechanism of glucocorticoid-mediated gene repression. Nuclear factor-kappa B is target for glucocorticoid-mediated interleukin 8 gene repression. J Biol Chem 1994; 269: 13289-95.
71. Kleinert H, Euchenhofer C, Ihrig-Biedert I, Forstermann U. In murine 3T3 fibroblasts, different second messenger pathways resulting in the induction of NO synthase II (iNOS) converge in the activation of transcription factor NF-kappaB. J Biol Chem 1996; 271: 6039-44.
72. Brostjan C, Anrather J, Csizmadia V, Natarajan G, Winkler H. Glucocorticoids inhibit E-selectin expression by targeting NFkappaB and not ATF/c-Jun. J Immunol 1997; 158: 3836-44.
73. Van de Stolpe A, Caldenhoven E, Stade BG, et al. 12-Otetradecanoylphorbol-13-acetate-and tumor necrosis factor alphamediated induction of intercellular adhesion molecule-1 is inhibited by dexamethasone. Functional analysis of the human intercellular adhesion molecular-1 promoter. J Biol Chem 1994; 269: 6185-92.
74. Simpson CS, Morris BJ. Activation of nuclear factor kappaB by nitric oxide in rat striatal neurones: differential inhibition of the p50 and p65 subunits by dexamethasone. J Neurochem 1999; 73: 353-61.
75. Kurokouchi K, Kambe F, Kikumori T, et al. Effects of glucocorticoids on tumor necrosis factor alpha-dependent activation of nuclear factor kappaB and expression of the intercellular adhesion molecule 1 gene in osteoblast-like ROS17/2.8 cells. J Bone Miner Res 2000; 15: 1707-15.
76. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS, Jr. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995; 270: 283-6.
77. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995; 270: 286-90.
78. Jonat C, Rahmsdorf HJ, Park KK, et al. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell 1990; 62: 1189-204.
79. Konig H, Ponta H, Rahmsdorf HJ, Herrlich P. Interference between pathway-specific transcription factors: glucocorticoids antagonize phorbol ester-induced AP-1 activity without altering AP-1 site occupation in vivo. EMBO J 1992; 11: 2241-6.
80. Adcock IM, Ito K, Barnes PJ. Glucocorticoids: effects on gene transcription. Proc Am Thorac Soc 2004; 1: 247-54.
81. Lonard DM, O'Malley B W. Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Mol Cell 2007; 27: 691-700.
82. Huang ZQ, Li J, Sachs LM, Cole PA, Wong J. A role for cofactorcofactor and cofactor-histone interactions in targeting p300, SWI/SNF and Mediator for transcription. EMBO J 2003; 22: 2146-55.
83. De Bosscher K, Vanden Berghe W, Haegeman G. Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J Neuroimmunol 2000; 109: 16-22.
84. De Bosscher K, Vanden Berghe W, Haegeman G. Glucocorticoid repression of AP-1 is not mediated by competition for nuclear coactivators. Mol Endocrinol 2001; 15: 219-27.
85. Ito K, Jazrawi E, Cosio B, Barnes PJ, Adcock IM. p65-activated histone acetyltransferase activity is repressed by glucocorticoids: mifepristone fails to recruit HDAC2 to the p65-HAT complex. J Biol Chem 2001; 276: 30208-15.
86. Ito K, Barnes PJ, Adcock IM. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol 2000; 20: 6891-903.
87. Luecke HF, Yamamoto KR. The glucocorticoid receptor blocks PTEFb recruitment by NFkappaB to effect promoter-specific transcriptional repression. Genes Dev 2005; 19: 1116-27.
88. Nissen RM, Yamamoto KR. The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev 2000; 14: 2314-29.
89. Beck IM, Vanden Berghe W, Vermeulen L, et al. Altered subcellular distribution of MSK1 induced by glucocorticoids contributes to NF-kappaB inhibition. EMBO J 2008; 27: 1682-93.
90. Heck S, Kullmann M, Gast A, et al. A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1. EMBO J 1994; 13: 4087-95.
91. Liden J, Delaunay F, Rafter I, Gustafsson J, Okret S. A new function for the C-terminal zinc finger of the glucocorticoid receptor. Repression of RelA transactivation. J Biol Chem 1997; 272: 21467-72.
92. Caldenhoven E, Liden J, Wissink S, et al. Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids. Mol Endocrinol 1995; 9: 401-12.
93. Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA, Baldwin AS Jr. Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. Mol Cell Biol 1995; 15: 943-53.
94. Liberman AC, Druker J, Refojo D, Holsboer F, Arzt E. Glucocorticoids inhibit GATA-3 phosphorylation and activity in T cells. FASEB J 2009; 23: 1558-71.
95. Maneechotesuwan K, Yao X, Ito K, et al. Suppression of GATA-3 nuclear import and phosphorylation: a novel mechanism of corticosteroid action in allergic disease. PLoS Med 2009; 6: e1000076.
96. Ou XM, Chen K, Shih JC. Glucocorticoid and androgen activation of monoamine oxidase A is regulated differently by R1 and Sp1. J Biol Chem 2006; 281: 21512-25.
97. Tuckermann JP, Reichardt HM, Arribas R, Richter KH, Schutz G, Angel P. The DNA binding-independent function of the glucocorticoid receptor mediates repression of AP-1-dependent genes in skin. J Cell Biol 1999; 147: 1365-70.
98. Reichardt HM, Kaestner KH, Tuckermann J, et al. DNA binding of the glucocorticoid receptor is not essential for survival. Cell 1998; 93: 531-41.
99. Reichardt HM, Tuckermann JP, Gottlicher M, et al. Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J 2001; 20: 7168-73.
100. Tai TC, Claycomb R, Her S, Bloom AK, Wong DL. Glucocorticoid responsiveness of the rat phenylethanolamine N-methyltransferase gene. Mol Pharmacol 2002; 61: 1385-92.
101. Adams M, Meijer OC, Wang J, Bhargava A, Pearce D. Homodimerization of the glucocorticoid receptor is not essential for response element binding: activation of the phenylethanolamine N-methyltransferase gene by dimerization-defective mutants. Mol Endocrinol 2003; 17: 2583-92.
102. Abraham SM, Lawrence T, Kleiman A, et al. Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J Exp Med 2006; 203: 1883-9.
103. Belvisi MG, Wicks SL, Battram CH, et al. Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J Immunol 2001; 166: 1975-82.
104. Vayssiere BM, Dupont S, Choquart A, et al. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol 1997; 11: 1245-55.
105. De Bosscher K, Vanden Berghe W, Beck IM, et al. A fully dissociated compound of plant origin for inflammatory gene repression. Proc Natl Acad Sci USA 2005; 102: 15827-32.
106. Dewint P, Gossye V, De Bosscher K, et al. A plant-derived ligand favoring monomeric glucocorticoid receptor conformation with impaired transactivation potential attenuates collagen-induced arthritis. J Immunol 2008; 180: 2608-15.
107. Zhang Z, Zhang ZY, Schluesener HJ. Compound A, a plant origin ligand of glucocorticoid receptors, increases regulatory T cells and M2 macrophages to attenuate experimental autoimmune neuritis with reduced side effects. J Immunol 2009; 183: 3081-91.
108. So AY, Chaivorapol C, Bolton EC, Li H, Yamamoto KR. Determinants of cell-and gene-specific transcriptional regulation by the glucocorticoid receptor. PLoS Genet 2007; 3: e94.
109. Besedovsky HO, del Rey A. Regulating inflammation by glucocorticoids. Nat Immunol 2006; 7: 537.
110. Leung DY, Bloom JW. Update on glucocorticoid action and resistance. J Allergy Clin Immunol 2003; 111: 3-22; quiz 23.
111. Bauer ME, Papadopoulos A, Poon L, et al. Altered glucocorticoid immunoregulation in treatment resistant depression. Psychoneuroendocrinology 2003; 28: 49-65.
112. Bauer ME, Vedhara K, Perks P, Wilcock GK, Lightman SL, Shanks N. Chronic stress in caregivers of dementia patients is associated with reduced lymphocyte sensitivity to glucocorticoids. J Neuroimmunol 2000; 103: 84-92.
113. Luz C, Collaziol D, Preissler T, da Cruz IM, Glock L, Bauer ME. Healthy aging is associated with unaltered production of immunoreactive growth hormone but impaired neuroimmunomodulation. Neuroimmunomodulation 2006; 13: 160-9.
114. Hearing SD, Norman M, Smyth C, Foy C, Dayan CM. Wide variation in lymphocyte steroid sensitivity among healthy human volunteers. J Clin Endocrinol Metab 1999; 84: 4149-54.
115. Van den Akker EL, Russcher H, van Rossum EF, et al. Glucocorticoid receptor polymorphism affects transrepression but not transactivation. J Clin Endocrinol Metab 2006; 91: 2800-3.
116. Webster JC, Oakley RH, Jewell CM, Cidlowski JA. Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: a mechanism for the generation of glucocorticoid resistance. Proc Natl Acad Sci USA 2001; 98: 6865-70.
117. Galigniana MD, Piwien-Pilipuk G, Assreuy J. Inhibition of glucocorticoid receptor binding by nitric oxide. Mol Pharmacol 1999; 55: 317-23.
118. Wallace AD, Cidlowski JA. Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocorticoids. J Biol Chem 2001; 276: 42714-21.
119. Levitt NS, Lambert EV, Woods D, Hales CN, Andrew R, Seckl JR. Impaired glucose tolerance and elevated blood pressure in low birth weight, nonobese, young south african adults: early programming of cortisol axis. J Clin Endocrinol Metab 2000; 85: 4611-8.
120. Reynolds RM, Walker BR, Syddall HE, Andrew R, Wood PJ, Whorwood CB, Phillips DI. Altered control of cortisol secretion in adult men with low birth weight and cardiovascular risk factors. J Clin Endocrinol Metab 2001; 86: 245-50.
121. Edwards CR, Benediktsson R, Lindsay RS, Seckl JR. Dysfunction of placental glucocorticoid barrier: link between fetal environment and adult hypertension? Lancet 1993; 341: 355-7.
122. Chikanza IC, Kozaci DL. Corticosteroid resistance in rheumatoid arthritis: molecular and cellular perspectives. Rheumatology (Oxford) 2004; 43: 1337-45.
123. Seki M, Ushiyama C, Seta N, et al. Apoptosis of lymphocytes induced by glucocorticoids and relationship to therapeutic efficacy in patients with systemic lupus erythematosus. Arthritis Rheum 1998; 41: 823-30.
124. Hearing SD, Norman M, Probert CS, Haslam N, Dayan CM. Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes. Gut 1999; 45: 382-8.
125. Williams GA, Haller JA, Kuppermann BD, et al. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol 2009; 147: 1048-54, 1054 e1-2.
126. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35: 360-2.
127. Leung D. Superantigens, steroid insensitivity and innate immunity in atopic eczema. Acta Derm Venereol Suppl (Stockh) 2005: 11-5.
128. Faubion WA Jr., Loftus EV Jr., Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255-60.
129. Matysiak M, Makosa B, Walczak A, Selmaj K. Patients with multiple sclerosis resisted to glucocorticoid therapy: abnormal expression of heat-shock protein 90 in glucocorticoid receptor complex. Mult Scler 2008; 14: 919-26.
130. Fiorucci E, Lucantoni G, Paone G, et al. Colchicine, cyclophosphamide and prednisone in the treatment of mildmoderate idiopathic pulmonary fibrosis: comparison of three currently available therapeutic regimens. Eur Rev Med Pharmacol Sci 2008; 12: 105-11.
131. De Boeck K, De Baets F, Malfroot A, Desager K, Mouchet F, Proesmans M. Do inhaled corticosteroids impair long-term growth in prepubertal cystic fibrosis patients? Eur J Pediatr 2007; 166: 23-8.
132. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997; 155: 542-8.
133. Yan ZQ, Hansson GK. Innate immunity, macrophage activation, and atherosclerosis. Immunol Rev 2007; 219: 187-203.
134. Peter JV, John P, Graham PL, Moran JL, George IA, Bersten A. Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis. Br Med J 2008; 336: 1006-9.